UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (MARK ONE) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarter ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-42430 Tavia Acquisition Corp. (Exact Name of Registrant as Specified in Its Charter) Cayman Islands N/A (State or other jurisdiction of inc ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (MARK ONE) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarter ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-42430 Tavia Acquisition Corp. (Exact Name of Registrant as Specified in Its Charter) Cayman Islands N/A (State or other jurisdiction of inc ...

FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38114 AVENUE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of in ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________________ to _______________ Commission file number 001-38299 cbdMD, INC. (Exact Name of Registrant as Specified in its Charter) North ...

Exhibit 99.1 Septerna Highlights Business Progress and Reports First Quarter 2025 Financial Results Announced Global Collaboration with Novo Nordisk to Develop Oral Small Molecules for Metabolic Diseases with Over $2.2 Billion in Potential Milestone Payments On Track to Select a Next-Generation Oral Small Molecule PTH1R Agonist to Accelerate Toward the Clinic Later in 2025 Expect to Initiate Phase 1 Trial for SEP-631, MRGPRX2 NAM Program for Mast Cell Diseases, in Third Quarter of 2025 Ended First Quarter 2 ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________________ FORM 10-Q _____________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 Or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37524 _____________________________ vTv Therapeuti ...

Exhibit 99.1 Virgin Galactic Announces First Quarter 2025 Financial Results and Provides Business Update ORANGE COUNTY, CALIFORNIA – May 15, 2025 – Virgin Galactic Holdings, Inc. (NYSE: SPCE) ("Virgin Galactic" or the "Company") today announced its financial results for the first quarter ended March 31, 2025 and provided a business update. Michael Colglazier, Chief Executive Officer of Virgin Galactic said, "The first quarter demonstrated strong progress advancing the build of our new SpaceShips and keeping ...

Financial Performance - The company reported net losses of $5.5 million for Q1 2025, compared to $7.1 million for Q1 2024, with an accumulated deficit of $356.9 million as of March 31, 2025[145]. - The net loss for the three months ended March 31, 2025 was $5.5 million, an improvement of 22.7% compared to a net loss of $7.1 million in the same period of 2024[165]. - During the three months ended March 31, 2025, net cash used in operating activities was $6.2 million, compared to $5.3 million in the same period of 2024, indicating an increase of 17.0%[182]. Cash Position - As of March 31, 2025, the company had cash and cash equivalents of $7.4 million, which is expected to fund operations only until September 2025[147]. - As of March 31, 2025, the company had cash and cash equivalents of $7.4 million, which is expected to fund operations into September 2025[172]. - The company raised $1.7 million from the exercise of PIPE Warrants and Offering Warrants on April 21, 2025[174]. Research and Development - The company initiated the RENEW Phase 2 clinical trial of LTI-03 in May 2025, aiming to enroll approximately 120 patients across up to 50 sites globally[141]. - The RENEW trial will assess the safety and efficacy of LTI-03, with a primary endpoint focused on treatment-emergent adverse events over 24 weeks[142]. - The company plans to continue its research and development of LTI-03 and LTI-01, expecting substantial increases in expenses related to ongoing activities[184]. Operating Expenses - For the three months ended March 31, 2025, total operating expenses decreased to $5.6 million from $7.2 million in the same period of 2024, representing a reduction of approximately 22.1%[165]. - Research and development expenses for the three months ended March 31, 2025 were $3.1 million, down from $3.5 million in the same period of 2024, a decrease of 11.4% primarily due to delays in clinical development[166]. - General and administrative expenses decreased to $2.5 million for the three months ended March 31, 2025, compared to $3.7 million in 2024, reflecting a reduction of 32.4% mainly from decreased professional fees[169]. Financing Activities - The company has financed operations through $145.5 million in net proceeds from common stock sales and $17.7 million from a public offering in May 2024[144]. - The company completed a follow-on public offering in May 2024, raising net proceeds of $17.7 million from the sale of 4,273,505 shares[154]. - The company entered into an "at the market offering" agreement with H.C. Wainwright for an aggregate offering price of up to $13.7 million[148]. - The company anticipates needing additional capital to fund operations, which may be obtained through equity or debt financings, strategic collaborations, or licensing arrangements[171]. Accounting and Compliance - No material changes to critical accounting estimates were reported for the three months ended March 31, 2025[192]. - Recent accounting standards reviewed will not have a material impact on the condensed consolidated financial statements[193]. - The company qualifies as a smaller reporting company and is not required to provide certain market risk disclosures[194]. Future Outlook - The company anticipates continued operating losses due to ongoing research and development activities[146]. - The company has a total potential obligation of approximately $16.9 million under a master services agreement with a third-party CRO for clinical research[189]. - The company has not generated any revenue from product sales and does not expect to do so in the foreseeable future[155].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ (Exact Name of Company as Specified in its Charter) Maryland 001-36695 (Commission File No.) 38-3941859 (I.R.S. Employer Identification No.) (State of ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________________ FORM 10-Q _____________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____ to ____ Commission File Number: 001-39757 ______________________________ Velo3D, Inc. ________ ...